These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 1764869)

  • 21. Pharmacokinetics and pharmacodynamics of famotidine in children.
    James LP; Marshall JD; Heulitt MJ; Wells TG; Letzig L; Kearns GL
    J Clin Pharmacol; 1996 Jan; 36(1):48-54. PubMed ID: 8932543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery.
    Kraus G; Krishna DR; Chmelarsch D; Schmid M; Klotz U
    Clin Pharmacokinet; 1990 Jan; 18(1):77-81. PubMed ID: 2311331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of famotidine in infants.
    James LP; Marotti T; Stowe CD; Farrar HC; Taylor BJ; Kearns GL
    J Clin Pharmacol; 1998 Dec; 38(12):1089-95. PubMed ID: 11301560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saturable urinary excretion kinetics of famotidine in the dog.
    Boom SP; Hoet S; Russel FG
    J Pharm Pharmacol; 1997 Mar; 49(3):288-92. PubMed ID: 9231347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cefetamet pivoxil clinical pharmacokinetics.
    Blouin RA; Stoeckel K
    Clin Pharmacokinet; 1993 Sep; 25(3):172-88. PubMed ID: 8222459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients.
    Saima S; Echizen H; Yoshimoto K; Ishizaki T
    J Clin Pharmacol; 1990 Feb; 30(2):159-62. PubMed ID: 2312768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute effects of ranitidine, famotidine and omeprazole on plasma gastrin in the rat.
    Decktor DL; Pendleton RG; Kellner AT; Davis MA
    J Pharmacol Exp Ther; 1989 Apr; 249(1):1-5. PubMed ID: 2565384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
    Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
    Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of famotidine in patients with cystic fibrosis.
    Maish WA; McCubbin MM; Letzig LG; Farrar HC; Kearns GL
    J Clin Pharmacol; 1998 Nov; 38(11):1010-6. PubMed ID: 9824781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of famotidine in man.
    Kroemer H; Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
    Tahara H; Kusuhara H; Chida M; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1187-94. PubMed ID: 16291876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of H2 antagonists on the differential secretion of triamterene and its sulfate conjugate metabolite by the isolated perfused rat kidney.
    Muirhead MR; Somogyi AA
    Drug Metab Dispos; 1991; 19(2):312-6. PubMed ID: 1676629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of ranitidine and famotidine in healthy elderly subjects: a double-blind, placebo-controlled comparison.
    Bisson C; St-Laurent M; Michaud JT; LeBel M
    Pharmacotherapy; 1993; 13(1):3-9. PubMed ID: 8437966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of hepatic disease on the pharmacokinetics of famotidine and effects of famotidine on hepatic hemodynamics and peptic ulcer.
    Ohnishi K
    Hepatogastroenterology; 1990 Jul; 37 Suppl 1():6-10. PubMed ID: 2210613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
    Lameire N; Rosenkranz B; Brockmeier D
    Scand J Gastroenterol Suppl; 1988; 146():100-10. PubMed ID: 2906455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.
    Klotz U; Arvela P; Rosenkranz B
    Eur J Clin Pharmacol; 1985; 28(6):671-5. PubMed ID: 2866097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.